Soo Lim, M.D. Ph.D.

CONTACT

Minji Sohn, Ph.D.

CONTACT

Lead Sponsor

Seoul National University Bundang Hospital

Collaborators

Age

20 - 80 years

Sex

ALL

Healthy Volunteers

No

•Type 2 diabetes patients with a glycated hemoglobin (HbA1c) level of 7.0 - 10.5% at screening
•Males or females aged 20-80 years
•Individuals who have been taking Metformin (≥ 500mg) with or without a DPP-4 inhibitor (such as Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Alogliptin, Teneligliptin, Anagliptin, Evogliptin) for at least the past 3 months
•Body mass index ≥ 23 kg/m²
•Estimated glomerular filtration ratio (eGFR) ≥ 60 ml/min/1.73m²

•Patients with Type 1 Diabetes, Gestational Diabetes, or secondary diabetes due to other causes
•Patients with a history of acute cardiovascular disease within the last 3 months prior to the screening visit
•Pregnant or breastfeeding patients, or patients not using contraception. Patients with chronic Hepatitis B or C (excluding healthy carriers of Hepatitis B), or liver disease (aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 3 times the upper limit of normal)
•Patients with heart failure or a history of heart failure
•Individuals with a history of cancer within the past 5 years (excluding those adequately treated for squamous cell carcinoma or thyroid cancer)
•Patients who have participated in another clinical study within the last 30 days
•Alcohol addiction
•Patients for whom the use of Enavogliflozin or Pioglitazone is contraindicated
•Patients taking other oral hypoglycemic agents or insulin or other investigational drugs
•Patients deemed unsuitable for the study based on the investigator's judgment